Search results for " antifungal agents"

showing 10 items of 11 documents

Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemi…

2019

Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, partic…

0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazolePLOS ONE
researchProduct

Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?

2016

Background Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. Methods Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in the…

0301 basic medicineCandida spp; Invasive fungal infections; Sepsismedicine.medical_specialtyAntifungal AgentsSepsi030106 microbiologyMycoseSubgroup analysisCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicineInvasive fungal infectionRandomized controlled trialRisk FactorsInvasive fungal infectionslawSepsisIntensive caremedicineHumansAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineCandidaCandida sppProphylaxisbusiness.industryIncidence (epidemiology)Risk FactorCandidiasismedicine.diseaseConfidence intervalCritical careFungalMycosesRelative riskCandida sppCandidiasiCandida spp; Invasive fungal infections; Sepsis; Antifungal Agents; Candida; Humans; Risk Factors; Candidiasis; Mycoses; Critical Care and Intensive Care MedicineInvasive fungal diseasebusinessResearch ArticleHuman
researchProduct

MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management

2016

Abstract Introduction A majority of invasive Candida infections occur in medical wards; however, evidence for management in this setting is scarce and based primarily on the intensive care or surgical setting. On behalf of the Italian Society for Anti-Infective Therapy (SITA) and the Italian Federation of Associations of Hospital Doctors on Internal Medicine (FADOI), the MEDICAL group produced practical management algorithms for patients in internal medicine wards. Methods The MEDICAL group panel, composed of 30 members from internal medicine, infectious disease, clinical pharmacology, clinical microbiology and clinical epidemiology, provided expert opinion through the RAND/UCLA method. Res…

0301 basic medicineMedical wardAntifungal AgentsConsensusInvasiveCritical CareDelphi TechniqueClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Algorithms; Antifungal Agents; Candidiasis Invasive; Consensus; Critical Care; Delphi Technique; Early Diagnosis; Echinocandins; Humans; Internal Medicine; Italy; Practice Guidelines as Topic; Severity of Illness Index; Internal Medicine030106 microbiologyeducationDelphi methodInvasive candidiasiSettore MED/17 - MALATTIE INFETTIVESeverity of Illness Indexlaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinelawIntensive careSeverity of illnessMedical consensusInternal MedicineMedicineHumansCandidiasis InvasiveClinical severity030212 general & internal medicineRisk stratificationcomputer.programming_languageClinical pharmacologybusiness.industryCandidiasisClinical severity; Invasive candidiasis; Medical wards; Risk stratificationInvasive candidiasismedicine.diseaseMedical wardsInvasive candidiasisEarly DiagnosisItalyInfectious disease (medical specialty)Practice Guidelines as TopicbusinessClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Internal MedicinecomputerAlgorithmDelphiAlgorithms
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

Low dosage liposomal amphotericin B in the treatment of Candida infections in critically ill patients.

2011

Antifungal AgentsTreatment OutcomeCritical care candida sepsisAmphotericin BCritical IllnessCandidiasisHumansSettore MED/41 - AnestesiologiaPilot ProjectsAmphotericin B; administration /&/ dosage Antifungal Agents; administration /&/ dosage Candidiasis; drug therapy Critical Illness Humans Middle Aged Pilot Projects Treatment OutcomeMiddle Agedadministration /&/ dosagedrug therapy
researchProduct

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Management of infections in cirrhotic patients: Report of a Consensus Conference

2014

a b s t r a c t The statements produced by the consensus conference on infection in end-stage liver disease promoted by the Italian Association for the Study of the Liver, are here reported. The topics of epidemiology, risk factors, diagnosis, prophylaxis, and treatment of infections in patient with compensated and decompensated liver cirrhosis were reviewed by a scientific board of experts who proposed 26 statements that were graded according to level of evidence and strength of recommen- dation, and approved by an independent jury. Each topic was explored focusing on the more relevant clinical questions. By systematic literature search of available evidence, comparison and discussion of e…

Fungal infectionLiver Cirrhosismedicine.medical_specialtyAntifungal Agentsmedia_common.quotation_subjectInfectionsGastroenterologyBacterial infection; Cirrhosis; Fungal infections; Infections; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Evidence-Based Medicine; Humans; Liver Cirrhosis; Mycoses; Hepatology; GastroenterologyLiver diseaseFungal infectionsJuryInternal medicineEpidemiologymedicineHumansIn patientGrading (education)Bacterial infection; Cirrhosis; Fungal infections; Infectionsmedia_commonCirrhosiEvidence-Based MedicineHepatologybusiness.industryConsensus conferenceGastroenterologyEvidence-based medicineBacterial Infectionsmedicine.diseaseAnti-Bacterial AgentsMycosesCirrhosisFamily medicineBacterial infectionbusinessInfectionSystematic search
researchProduct

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

2001

Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P=.0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, p…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAdolescentFeverOpportunistic infectionBacteremiaNeutropeniaInternal medicineMedicineHumansMycosisLeukopeniabusiness.industryOdds ratioAntibiotic ProphylaxisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseSurgeryLeukemia Myeloid AcuteInfectious DiseasesAntibiotic Prophylaxis/utilization; Antifungal Agents/therapeutic use; Bacteremia/epidemiology; Fever/complications; Leukemia Myeloid Acute/complications; Neutropenia/complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complicationsBacteremiaChemoprophylaxisFemalemedicine.symptombusinessFebrile neutropeniaClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct